rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
Study sponsor: AKARI Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-08-29Actual
Enrollment · participants15Actual
Source updated2025-04-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.